Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEAT study of lenalidomide + cyclophosphamide + prednisone in lenalidomide-pretreated relapsed/refractory multiple myeloma
NL-OMON41710Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide, cyclophosphamide and prednisone in multiple myeloma (MM) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Dose-limiting toxicity, maximum tolerated dose, and recommended phase 2 dose and Overall response rate. Started Aug 2011; status: active, not recruiting.
02
Drugs
lenalidomidecyclophosphamideprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON41710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41710.